Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Of course Willie will push the use of LFTs, his job requires him to advocate getting some normality back to the airline industry. Ultimately testing requirements and standards will be set out by Governments not what IATA recommend.
IATA have no ability to impose anything on individual airlines - you can't 'make a deal' with IATA in that sense. Any deals will have to be with individual directly airlines (or their parent group).
These were the notes I made on the diagnostic part of the presentation / Q&A if they are of help to anyone.
• The global showcase enjoyed through the Covid testing development is extremely high profile and that’s already generating more interest from external partners regarding the use of Affimers. Really puts Avacta on the map.
• Affimer platform offers a wide range of diagnostic opportunities. Clear focus on diagnostic development for clinical, consumer and professional use.
• Still looking and discussing licencing opportunities such as that with Astrea.
• Inhouse diagnostic pipeline which will be launched under AffiDX brand which are currently in development:
o Cortisol: Stress
o CRP: Sepsis
o B12: Anemia
• Clear focus on developing partnerships with medium and large diagnostic partners. A number of products will be bought to market both inhouse under the AffiDX brand and diagnostic partners over the coming months and years.
• One of the best, if not, the best Covid antigen tests available.
• A few weeks for ABDX tech transfer. Focussing manufacturing capability on ABDX, other UK, EU and overseas manufacturers. Currently producing AffiDX through GAD – continue to scale production with them and others in the UK and EU.
• Manufacturing capacity available to AVCT in the UK is between 5 and 30 million tests a month (from Q3). The higher number depends on getting access to government supplied manufacturing infrastructure.
• Quite a long way down the route in securing additional overseas capacity, providing 1m tests a day with quite a short tech transfer (6 to 8 weeks), lead time and a lower cost of goods. Avacta are pushing forwards in getting the transfer done with overseas manufactures so they can switch on that supply as demand requires.
• In terms of route to mark Avacta have ‘A LOT’ of commercial negotiations with end users, customers and distributors ongoing throughout the UK, EEA and APAC. A number of other overseas markets look very attractive.
• More than one possible route to FDA approval at the moment. Will update the market when appropriate.
• Working very closely with Medusa-19 with a joint goal of gaining authorisation for self-testing. Unable to comment further due to confidentiality agreements.
• Calibre are a very high-quality global partner. They will focus on the EEA and UK with relatively large number of customers with varying sales volume sizes. Avacta will focus on very high volume large corporate customers with direct sales for workforce testing as well as service providers for workforce testing. Avacta is specifically targeting sales to travel industry, events company, health and social care sectors.
• There’s a number of markets that have emerged particular in the APAC region, approaching Avacta looking for high quality tests of UK / EU origin.
• ‘Multiple commercial deals with distributors and end users expected in H2’
• Scaling manufacturing is key to meeting demand.
Utter rubbish. Completely inaccurate. No mainstream commercial aircraft uses 100% recycled air, it’s more like 50/50 fresh/recycled with all air recycled around every 5-10 minutes. On top of this, they all use HEPA filters which filter out 99% of bacteria and viruses. If the person next to you has a cold you might catch it, someone a few rows back is very unlikely to give you anything...